Header Logo

Connection

WAYNE L HOFSTETTER to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications WAYNE L HOFSTETTER has written about Aged, 80 and over.
WAYNE L HOFSTETTER
Connection Strength
0.976
Aged, 80 and over
  1. Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer? Dis Esophagus. 2019 Dec 13; 32(10):1-6.
    View in: PubMed
    Score: 0.045
  2. Preoperative Chemoradiation Therapy Versus Chemotherapy in Patients Undergoing Modified En Bloc Esophagectomy for Locally Advanced Esophageal Adenocarcinoma: Is Radiotherapy Beneficial? Ann Thorac Surg. 2016 Apr; 101(4):1262-9; discussion 1969-70.
    View in: PubMed
    Score: 0.035
  3. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016 Mar; 101(3):1075-80; Discussion 1080-1.
    View in: PubMed
    Score: 0.034
  4. Endoscopic Ultrasound Estimates for Tumor Depth at the Gastroesophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection. Ann Thorac Surg. 2015 Nov; 100(5):1812-6.
    View in: PubMed
    Score: 0.033
  5. Diaphragmatic hernia after esophagectomy in 440 patients with long-term follow-up. Ann Thorac Surg. 2013 Oct; 96(4):1138-1145.
    View in: PubMed
    Score: 0.029
  6. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69.
    View in: PubMed
    Score: 0.029
  7. Omental reinforcement of the thoracic esophagogastric anastomosis: an analysis of leak and reintervention rates in patients undergoing planned and salvage esophagectomy. J Thorac Cardiovasc Surg. 2012 Nov; 144(5):1146-50.
    View in: PubMed
    Score: 0.027
  8. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008 Sep; 32(9):1404-11.
    View in: PubMed
    Score: 0.021
  9. Localized Gastroesophageal Adenocarcinoma in the Elderly: Is Age a Factor Associated with Suboptimal Treatment? Oncology. 2023; 101(3):153-158.
    View in: PubMed
    Score: 0.014
  10. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
    View in: PubMed
    Score: 0.014
  11. Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery. Ann Surg. 2021 12 01; 274(6):1099-1106.
    View in: PubMed
    Score: 0.013
  12. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study. Br J Surg. 2021 04 30; 108(4):403-411.
    View in: PubMed
    Score: 0.012
  13. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. 2021 04 01; 273(4):751-757.
    View in: PubMed
    Score: 0.012
  14. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2020 08; 272(2):311-318.
    View in: PubMed
    Score: 0.012
  15. Time trends and predictors of survival in surgically resected early-stage non-small cell lung cancer patients. J Surg Oncol. 2020 Sep; 122(3):495-505.
    View in: PubMed
    Score: 0.012
  16. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020 05 10; 38(14):1569-1579.
    View in: PubMed
    Score: 0.011
  17. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer. 2020 07; 21(4):341-348.
    View in: PubMed
    Score: 0.011
  18. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. Medicine (Baltimore). 2020 Feb; 99(9):e19295.
    View in: PubMed
    Score: 0.011
  19. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604.
    View in: PubMed
    Score: 0.011
  20. Persistent opioid use is associated with worse survival after lobectomy for stage I non-small cell lung cancer. Pain. 2019 10; 160(10):2365-2373.
    View in: PubMed
    Score: 0.011
  21. Perioperative outcomes among chronic opioid users who receive lobectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020 02; 159(2):691-702.e5.
    View in: PubMed
    Score: 0.011
  22. Persistent Opioid Use Among the Elderly After Lung Resection: A SEER-Medicare Study. Ann Thorac Surg. 2020 01; 109(1):194-202.
    View in: PubMed
    Score: 0.011
  23. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes. Ann Surg. 2019 04; 269(4):663-670.
    View in: PubMed
    Score: 0.011
  24. Benchmarking Complications Associated with Esophagectomy. Ann Surg. 2019 02; 269(2):291-298.
    View in: PubMed
    Score: 0.011
  25. Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. J Thorac Cardiovasc Surg. 2019 04; 157(4):1648-1655.
    View in: PubMed
    Score: 0.010
  26. Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series. J Surg Oncol. 2018 Sep; 118(3):518-524.
    View in: PubMed
    Score: 0.010
  27. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295.
    View in: PubMed
    Score: 0.010
  28. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. J Gastrointest Surg. 2018 11; 22(11):2013-2019.
    View in: PubMed
    Score: 0.010
  29. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90.
    View in: PubMed
    Score: 0.010
  30. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2018 05 01; 53(5):960-966.
    View in: PubMed
    Score: 0.010
  31. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology. 2018; 94(6):345-353.
    View in: PubMed
    Score: 0.010
  32. Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer. Ann Thorac Surg. 2018 06; 105(6):1671-1677.
    View in: PubMed
    Score: 0.010
  33. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018 07; 128(1):154-160.
    View in: PubMed
    Score: 0.010
  34. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Feb; 105(2):418-424.
    View in: PubMed
    Score: 0.010
  35. Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel. Ann Thorac Surg. 2017 Dec; 104(6):1821-1828.
    View in: PubMed
    Score: 0.010
  36. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.010
  37. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655.
    View in: PubMed
    Score: 0.010
  38. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248.
    View in: PubMed
    Score: 0.010
  39. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. Med Oncol. 2017 Aug; 34(8):135.
    View in: PubMed
    Score: 0.010
  40. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017 08; 124(2):318-324.
    View in: PubMed
    Score: 0.010
  41. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017 Apr 25; 8(17):28696-28710.
    View in: PubMed
    Score: 0.009
  42. Patterns of Care and Treatment Outcomes of Elderly?Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base. J Thorac Oncol. 2017 07; 12(7):1152-1160.
    View in: PubMed
    Score: 0.009
  43. Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction? Ann Thorac Surg. 2017 Jun; 103(6):1710-1714.
    View in: PubMed
    Score: 0.009
  44. An age-period-cohort analysis of obesity and incident esophageal adenocarcinoma among white males. Dis Esophagus. 2017 02 01; 30(3):1-8.
    View in: PubMed
    Score: 0.009
  45. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382.
    View in: PubMed
    Score: 0.009
  46. Esophagectomy Following Endoscopic Resection of Submucosal Esophageal Cancer: a Highly Curative Procedure Even with Nodal Metastases. J Gastrointest Surg. 2017 01; 21(1):62-67.
    View in: PubMed
    Score: 0.009
  47. Results of Postdischarge Nursing Telephone Assessments: Persistent Symptoms Common Among Pulmonary Resection Patients. Ann Thorac Surg. 2016 Jul; 102(1):276-81.
    View in: PubMed
    Score: 0.009
  48. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw. 2016 02; 14(2):173-9.
    View in: PubMed
    Score: 0.009
  49. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer. 2016 Mar 15; 122(6):917-28.
    View in: PubMed
    Score: 0.009
  50. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer. 2015 Nov; 51(17):2545-52.
    View in: PubMed
    Score: 0.008
  51. Impact of a Fast-track Esophagectomy Protocol on Esophageal Cancer Patient Outcomes and Hospital Charges. Ann Surg. 2015 Jun; 261(6):1114-23.
    View in: PubMed
    Score: 0.008
  52. Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer. 2015; 15:1095.
    View in: PubMed
    Score: 0.008
  53. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. Oncology. 2015; 89(2):65-9.
    View in: PubMed
    Score: 0.008
  54. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
    View in: PubMed
    Score: 0.008
  55. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5.
    View in: PubMed
    Score: 0.008
  56. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9.
    View in: PubMed
    Score: 0.008
  57. Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. Clin Cancer Res. 2014 Apr 01; 20(7):1946-54.
    View in: PubMed
    Score: 0.007
  58. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
    View in: PubMed
    Score: 0.007
  59. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol Oncol. 2014 Feb; 8(1):142-9.
    View in: PubMed
    Score: 0.007
  60. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. Dis Esophagus. 2014 Feb-Mar; 27(2):168-75.
    View in: PubMed
    Score: 0.007
  61. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus. 2013 Sep-Oct; 26(7):708-15.
    View in: PubMed
    Score: 0.007
  62. Predictors of recurrent pulmonary metastases and survival after pulmonary metastasectomy for colorectal cancer. Ann Thorac Surg. 2012 Dec; 94(6):1802-9.
    View in: PubMed
    Score: 0.007
  63. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9.
    View in: PubMed
    Score: 0.007
  64. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
    View in: PubMed
    Score: 0.007
  65. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
    View in: PubMed
    Score: 0.007
  66. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012 Sep; 16(9):1696-704.
    View in: PubMed
    Score: 0.007
  67. Preoperative microvascular dysfunction: a prospective, observational study expanding risk assessment strategies in major thoracic surgery. Ann Thorac Surg. 2012 Jul; 94(1):226-33.
    View in: PubMed
    Score: 0.007
  68. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol. 2012 May; 7(5):833-40.
    View in: PubMed
    Score: 0.007
  69. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e231-9.
    View in: PubMed
    Score: 0.007
  70. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e345-51.
    View in: PubMed
    Score: 0.007
  71. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012 May 15; 118(10):2632-40.
    View in: PubMed
    Score: 0.006
  72. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol. 2011 Jul; 35(7):1045-53.
    View in: PubMed
    Score: 0.006
  73. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1967-72.
    View in: PubMed
    Score: 0.006
  74. A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients. Ann Surg. 2010 Oct; 252(4):611-7.
    View in: PubMed
    Score: 0.006
  75. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9.
    View in: PubMed
    Score: 0.006
  76. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology. 2010; 78(5-6):316-22.
    View in: PubMed
    Score: 0.006
  77. Comparison between established and the Worldwide Esophageal Cancer Collaboration staging systems. Ann Thorac Surg. 2010 Jun; 89(6):1797-1803, 1804.e1-3; discussion 1803-4.
    View in: PubMed
    Score: 0.006
  78. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer. 2009 Oct 01; 115(19):4450-8.
    View in: PubMed
    Score: 0.006
  79. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Mod Pathol. 2009 Dec; 22(12):1612-21.
    View in: PubMed
    Score: 0.006
  80. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg. 2009 Sep; 88(3):877-84; discussion 884-5.
    View in: PubMed
    Score: 0.006
  81. Outcomes with esophageal cancer radiation therapy. J Thorac Oncol. 2009 Jul; 4(7):880-8.
    View in: PubMed
    Score: 0.005
  82. Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg. 2009 Aug; 138(2):412-418.e1-2.
    View in: PubMed
    Score: 0.005
  83. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6.
    View in: PubMed
    Score: 0.005
  84. Esophageal tumor length is independently associated with long-term survival. Cancer. 2009 Feb 01; 115(3):508-16.
    View in: PubMed
    Score: 0.005
  85. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 01; 115(3):624-30.
    View in: PubMed
    Score: 0.005
  86. 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC). J Thorac Oncol. 2008 Sep; 3(9):979-84.
    View in: PubMed
    Score: 0.005
  87. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer. 2008 Mar 01; 112(5):1020-7.
    View in: PubMed
    Score: 0.005
  88. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007 Nov; 84(5):1685-92; discussion 1692-3.
    View in: PubMed
    Score: 0.005
  89. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer. J Thorac Oncol. 2007 Nov; 2(11):1022-8.
    View in: PubMed
    Score: 0.005
  90. Propensity-matched analysis of three techniques for intrathoracic esophagogastric anastomosis. Ann Thorac Surg. 2007 May; 83(5):1805-13; discussion 1813.
    View in: PubMed
    Score: 0.005
  91. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer. 2007 Feb 15; 109(4):658-67.
    View in: PubMed
    Score: 0.005
  92. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007 Jan 01; 109(1):125-34.
    View in: PubMed
    Score: 0.005
  93. Increased risk of aspiration and pulmonary complications after lung resection in head and neck cancer patients. Ann Thorac Surg. 2006 Dec; 82(6):1982-7; discussion 1987-8.
    View in: PubMed
    Score: 0.005
  94. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res. 2006 Aug 01; 12(15):4598-604.
    View in: PubMed
    Score: 0.004
  95. Malignant melanoma and bone resorption. Br J Cancer. 2006 May 22; 94(10):1496-503.
    View in: PubMed
    Score: 0.004
  96. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005 Dec; 80(6):1988-92; discussion 1992-3.
    View in: PubMed
    Score: 0.004
  97. Intrathoracic leaks following esophagectomy are no longer associated with increased mortality. Ann Surg. 2005 Sep; 242(3):392-9; discussion 399-402.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.